Nigel Martyn Bark MD
Associate Professor, Psychiatry & Behavioral Sciences, Albert Einstein College of Medicine
Join to View Full Profile
117 Constitution DrOrangeburg, NY 10962
Phone+1 845-359-7553
Fax+1 845-359-7553
Are you Dr. Bark?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 7 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Nigel Bark, MD is a board certified psychiatrist in Orangeburg, New York. He is currently licensed to practice medicine in New York and New Jersey. He is an Associate Professor at Albert Einstein College of Medicine.
Education & Training
University of Cambridge School of MedicineClass of 1966
Certifications & Licensure
NJ State Medical License Current
NY State Medical License 1976 - 2026
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics Start of enrollment: 2005 May 01
- An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia Start of enrollment: 2005 Nov 01
- Study of Vitamin D in the Severely Mentally Ill Start of enrollment: 2010 Jan 01
Publications & Presentations
PubMed
- Among the severely mentally ill, who responds to ziprasidone?Nigel Bark, Nicholas Lawson, Eileen Trigoboff, Rodica Varadi, Jeffery Grace
Clinical Schizophrenia & Related Psychoses. 2016-01-18 - 8 citationsPrisoner mental health in the USA.Nigel Bark
International Psychiatry. 2014-08-01 - 34 citationsEffects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: A randomiz...Robert C. Smith, Hua Jin, Chunbo Li, Nigel Bark, Anantha Shekhar
Schizophrenia Research. 2013-01-01
Authored Content
- Hydroxychloroquine - Does It Have Clinical Value in COVID-19? A Point, Counterpoint DiscussionNovember 2020
